Correlation between p53 expression and clinical-pathological characteristics of gastric cancer;Korelacija između ekspresije p53 i kliničkopatoloških osobina karcinoma želuca

Vojnosanitetski Pregled

Volumn 68, Issue 10, 2011, Pages 832-836

  Radovanović, Dragče ^a   Knežević, Milan ^a   Čanović, Dragan ^a   Aćimović, Ljubiša ^a  

^a Klinika za hirurgiju ^*  (Serbia)

Author keywords

Gene expression; Genes; Immunohistochemistry; p53; Sensitivity and specificity; Stomach neoplasms

Indexed keywords

MUTANT PROTEIN; PROTEIN P53;

ARTICLE; BLOOD VESSEL WALL; CANCER INVASION; CARCINOMA CELL; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ASSOCIATION; HUMAN; IMMUNOHISTOCHEMISTRY; INTESTINE METAPLASIA; LYMPH NODE; MOLECULAR PATHOLOGY; MUTATION RATE; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; STOMACH CANCER;

EID: 80053945105     PISSN: 00428450     EISSN: None     Source Type: Journal    
DOI: 10.2298/VSP1110832R     Document Type: Article

References (31)

1. Smith MG, Hold GL, Tahara E, El-Omar EM. Cellular and molecular aspects of gastric cancer. World J Gastroenterol 2006; 12(19): 2979-90.
2. National Foundation for Cancer research. Gastric cancer. Available from: www.nfcr.org/index.php
3. American Cancer Society. Global Cancer facts and Figures; 2nd ed. 2011.
4. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E et al. Cancer statistics. CA Cancer J Clin 2004; 54(1): 8-29.
5. Salvon-Harman JC, Cady B, Nikulasson S, Khettry U, Stone MD, Lavin P. Shifting proportions of gastric adenocarcinomas. Arch Surg 1994; 129(4): 381-9.
6. Devesa SS, Fraumeni JF Jr. The rising incidence of gastric cardia cancer. J Natl Cancer Inst 1999; 91(9): 747-9.
7. La Vecchia C, Negri E, Franceschi S, Gentile A. Family history and the risk of stomach and colorectal cancer. Cancer 1992; 70(1): 50-5.
8. Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH. Systematic population-based assessment of cancer risk in firstdegree relatives of cancer probands. J Natl Cancer Inst 1994; 86(21): 1600-8.
9. Machado JC, Soares P, Carneiro F, Rocha A, Beck S, Blin N et al. E-cadherin gene mutations provide a genetic basis for the phenotypic divergence of mixed gastric carcinomas. Lab Invest 1999; 79(4): 459-65.
10. Pharoah PD, Guilford P, Caldas C. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology 2001; 121(6): 1348-53.
11. Ascaño JJ, Frierson H Jr, Moskaluk CA, Harper JC, Roviello F, Jackson CE et al. Inactivation of the E-cadherin gene in sporadic diffuse-type gastric cancer. Mod Pathol 2001; 14(10): 942-9.
12. Kaurah P, MacMillan A, Boyd N, Senz J, De Luca A, Chun N et al. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA 2007; 297(21): 2410-1.
13. Carneiro F, Oliveira C, Suriano G, Seruca R. Molecular pathology of familial gastric cancer, with an emphasis on hereditary diffuse gastric cancer. J Clin Pathol 2008; 61(1): 25-30.
14. Scartozzi M, Galizia E, Freddari F, Berardi R, Cellerino R, Cascinu S. Molecular biology of sporadic gastric cancer: prognostic indicators and novel therapeutic approaches. Cancer Treat Rev 2004; 30(5): 51-9.
15. Harris AL. Mutant p53-the commonest genetic abnormality in human cancer. J Pathol 1990; 162(1): 5-6.
16. Harris CC, Hollestein M. Clinical implications of the p53 tumorsuppressor gene. N Engl J Med 1993; 329(18): 1318-27.
17. Komarova EA, Chamakov PM, Gudkov AV. TP53 in cancer origin and treatment. In: Cowell JK, editor. Molecular Genetic of Cancer. 2nd ed. Oxford: Bios; San Diego, CA: Academic Press, 2001. p. 195-216.
18. Oren M, Damalas A, Gottlieb T, Michael D, Taplick J, Leal JF et al. Regulation of p53: intricate loops and delicate balances. Ann NY Acad Sci 2002; 973: 374-83.
19. Ullrich SJ, Anderson CW, Mercer WE, Appella E. The p53 tumor suppressor protein, a modulator of cell proliferation. J Biol Chem 1992; 267(22): 15259-62.
20. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253(5015): 49-53.
21. Hurlimann J, Saraga EP. Expression of p53 protein in gastric carcinomas. Association with histologic type and prognosis. Am J Surg Pathol 1994; 18(12): 1247-53.
22. Gabbert HE, Müller W, Schneiders A, Meier S, Hommel G. The relationship of p53 expression to the prognosis of 418 patients with gastric carcinoma. Cancer 1995; 76(5): 720-6.
23. Varis A, Wolf M, Monni O, Vakkari ML, Kokkola A, Moskaluk C et al. Targets of gene amplification and over expression at 17q in gastric cancer. Cancer Res 2002; 62(9): 2625-9.
24. Starzynska T, Markiewski M, Domagala W, Marlicz K, Mietkiewski J, Roberts SA et al. The clinical significance of p53 accumulation in gastric carcinoma. Cancer 1996; 77(10): 2005-12.
25. Martin HM, Filipe MI, Morris RW, Lane DP, Silvestre F. p53 expression and prognosis in gastric carcinoma. Int J Cancer 2006; 50(6): 859-62.
26. Lazǎr D, Tǎban S, Sporea I, Dema A, Cornianu M, Lazǎr E et al. The immunohistochemical expression of the p53-protein in gastric carcinomas. Correlation with clinicopathological factors and survival of patients. Rom J Morphol Embryol 2010; 51(2): 249-57.
27. Kip1, p53 and Infiltration, Metastasis and Prognosis in Gastric Carcinoma. Chin Ger J Clin Oncol 2005; 4(3): 155-60.
28. Dong W, Sun J, Xu Y, Yu J. Changes of multiple genes in human gastric carcinomas. Chin J Cancer Res 2001; 13(3): 63-5.
29. Lane DP. Cancer. P53, guardian of the genome. Nature 1992; 358(6381): 15-6.
30. Yokobori T, Mimori K, Iwatsuki M, Ishii H, Onoyama I, Fukagawa T, et al. p53-Altered FBXW7 Expression Determines Poor Prognosis in Gastric Cancer Cases. Cancer Res 2009; 69(9): 3788-94.
31. Leung WK, To KF, Ng YP, Lee TL, Lau JY, Chan FK, et al. Association between cyclo-oxygenase-2 overexpression and missense p53 mutations in gastric cancer. Br J Cancer 2001; 84(3): 335-9.